New drug GenSci155 tested in healthy people for first time
NCT ID NCT07638800
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests the safety and tolerability of a new drug called GenSci155 in 68 healthy adults aged 18-60. Participants receive either the drug or a placebo by IV injection, with doses increasing in later groups. The study does not aim to treat any disease, but to gather initial safety data before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GenSci155 injection
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT TRIAL PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China